Telehealth care for patients with cardiometabolic disease
Evaluation of the Telehealth Integrated Care Model in Patients With Hyperlipidemia and Other Cardiometabolic Disease
This study tests whether a new telehealth care approach can help people with high cholesterol and other heart-related conditions feel better and be more satisfied with their treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1302 (estimated) |
| Ages | 16 Years to 85 Years |
| Sex | All |
| Sponsor | Peking University Third Hospital Academic / other |
| Locations | 1 site (Beijing, Beijing) |
| Trial ID | NCT06022575 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effectiveness of a telehealth integrated care model for patients with hyperlipidemia and other cardiometabolic diseases. It aims to assess clinical efficacy, resource utilization, health economics, and patient satisfaction through a combination of online and offline healthcare approaches. By analyzing the outcomes, the study seeks to provide evidence for the value of this integrated model in managing cardiometabolic conditions.
Who should consider this trial
Good fit: Ideal candidates are individuals aged 16 to 85 diagnosed with hyperlipidemia and at least one additional condition such as hypertension or type 2 diabetes.
Not a fit: Patients with severe cardiovascular issues, significant organ dysfunction, or those unable to complete a one-year follow-up may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could enhance the management and treatment outcomes for patients with cardiometabolic diseases.
How similar studies have performed: Other studies have shown promising results with telehealth approaches in chronic disease management, indicating potential for success in this integrated model.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 16 years, and ≤ 85 years; * Diagnosis as hyperlipidemia with at least one of the following disease: hypertension or type 2 diabetes mellitus; * Agreed to be enrolled in this study. Exclusion Criteria: * Undergone percutaneous coronary intervention within one year in our hospital; * Severe LV dysfunction, such as LV ejection fraction \< 35%, or congestive heart failure with New York Heart Association (NYHA) functional class IV or Killip class IV; * Structural heart disease, or severe arrhythmia; * Severe liver or kidney diseases, endocrinology diseases, hematologic diseases, rheumatic immune system diseases, and malignancy; * could not complete at least one-year-followup.
Where this trial is running
Beijing, Beijing
- Peking University Third Hospital — Beijing, Beijing, China (Recruiting)
Study contacts
- Principal investigator: Lin Zeng, Ph.D — Peking University Third Hospital
- Study coordinator: Lequn Zhou, Dr
- Email: zhoulequnde@126.com
- Phone: +86 1082266280
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.